CN104582701B - 减轻体重的方法 - Google Patents

减轻体重的方法 Download PDF

Info

Publication number
CN104582701B
CN104582701B CN201380033658.6A CN201380033658A CN104582701B CN 104582701 B CN104582701 B CN 104582701B CN 201380033658 A CN201380033658 A CN 201380033658A CN 104582701 B CN104582701 B CN 104582701B
Authority
CN
China
Prior art keywords
diabetes
methazolamide
treatment
insulin
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380033658.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN104582701A (zh
Inventor
肯·瓦尔德
盖伊·克里普纳
杰夫·尼克尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nayar Metabolism Co Ltd
Original Assignee
Verva Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verva Pharmaceuticals Ltd filed Critical Verva Pharmaceuticals Ltd
Publication of CN104582701A publication Critical patent/CN104582701A/zh
Application granted granted Critical
Publication of CN104582701B publication Critical patent/CN104582701B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
CN201380033658.6A 2012-05-24 2013-03-15 减轻体重的方法 Expired - Fee Related CN104582701B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261651335P 2012-05-24 2012-05-24
US61/651,335 2012-05-24
PCT/AU2013/000259 WO2013173858A1 (en) 2012-05-24 2013-03-15 A method of weight reduction

Publications (2)

Publication Number Publication Date
CN104582701A CN104582701A (zh) 2015-04-29
CN104582701B true CN104582701B (zh) 2018-01-16

Family

ID=49622926

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380033658.6A Expired - Fee Related CN104582701B (zh) 2012-05-24 2013-03-15 减轻体重的方法

Country Status (16)

Country Link
US (2) US20150174108A1 (enExample)
EP (1) EP2854806A4 (enExample)
JP (1) JP6438389B2 (enExample)
KR (1) KR20150023404A (enExample)
CN (1) CN104582701B (enExample)
AU (1) AU2013202981B2 (enExample)
BR (1) BR112014029302A2 (enExample)
CA (1) CA2874512A1 (enExample)
CO (1) CO7160083A2 (enExample)
HK (1) HK1209041A1 (enExample)
MX (1) MX2014014316A (enExample)
NZ (1) NZ702666A (enExample)
RU (1) RU2664442C2 (enExample)
SG (1) SG11201407786XA (enExample)
WO (1) WO2013173858A1 (enExample)
ZA (1) ZA201408703B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2106260B8 (en) 2007-01-25 2018-04-04 Naia Metabolic, Inc. Insulin sensitisers and methods of treatment
SG10201705388XA (en) * 2012-05-24 2017-07-28 Verva Pharmaceuticals Ltd A Method Of Improving Liver Function
US10039752B2 (en) * 2016-07-21 2018-08-07 Cipla Limited Methazolamide for the treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007114948A2 (en) * 2006-04-04 2007-10-11 The Brigham And Women's Hospital, Inc. Methods and compositions for inhibiting cell death

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2783241A (en) * 1957-02-26 S-acylimino-x-substituted-az-i
JP2000080047A (ja) * 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
US6946243B2 (en) * 2000-07-20 2005-09-20 Solvay Pharmaceuticals Gmbh Method of identifying compounds suitable for treatment and/or prophylaxis of obesity
AU2001280093A1 (en) * 2000-08-11 2002-02-25 Einar Stefansson Method for the prevention and treatment of retinopathy
PL377614A1 (pl) * 2003-03-18 2006-02-06 Novartis Ag Kompozycje zawierające kwasy tłuszczowe i aminokwasy
ES2639579T3 (es) * 2003-04-29 2017-10-27 Orexigen Therapeutics, Inc. Composiciones para afectar la pérdida de peso que comprende un antagonista opioide y bupropión
TW200526678A (en) 2003-08-01 2005-08-16 Janssen Pharmaceutica Nv Substituted indole-O-glucosides
EP2106260B8 (en) * 2007-01-25 2018-04-04 Naia Metabolic, Inc. Insulin sensitisers and methods of treatment
WO2011002011A1 (ja) * 2009-07-01 2011-01-06 キッセイ薬品工業株式会社 Sglt1阻害薬とdpp-iv阻害薬を組み合わせてなる医薬
EP3459558B1 (en) * 2010-06-25 2020-07-29 Aston University Glycoproteins having lipid mobilizing properties and therapeutic uses thereof
WO2012008549A1 (ja) * 2010-07-15 2012-01-19 武田薬品工業株式会社 複素環化合物
SG10201705388XA (en) * 2012-05-24 2017-07-28 Verva Pharmaceuticals Ltd A Method Of Improving Liver Function

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007114948A2 (en) * 2006-04-04 2007-10-11 The Brigham And Women's Hospital, Inc. Methods and compositions for inhibiting cell death

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Metformin and body weight;A Golay;《International Journal of Obesity》;20070724;第32卷;第61-72页 *

Also Published As

Publication number Publication date
US20150174108A1 (en) 2015-06-25
BR112014029302A2 (pt) 2017-06-27
KR20150023404A (ko) 2015-03-05
EP2854806A4 (en) 2015-11-18
ZA201408703B (en) 2018-07-25
AU2013202981B2 (en) 2014-11-13
WO2013173858A1 (en) 2013-11-28
HK1209041A1 (en) 2016-03-24
CO7160083A2 (es) 2015-01-15
JP6438389B2 (ja) 2018-12-12
CA2874512A1 (en) 2013-11-28
JP2015520759A (ja) 2015-07-23
CN104582701A (zh) 2015-04-29
RU2014150946A (ru) 2016-07-10
US20180333398A1 (en) 2018-11-22
EP2854806A1 (en) 2015-04-08
RU2664442C2 (ru) 2018-08-17
AU2013202981A1 (en) 2013-12-12
MX2014014316A (es) 2015-07-06
SG11201407786XA (en) 2015-03-30
NZ702666A (en) 2016-08-26

Similar Documents

Publication Publication Date Title
CN1960735B (zh) 药物组合在治疗胰岛素抗性中的应用
US20250325536A1 (en) Therapeutic uses of glp1r agonists
KR20130137628A (ko) 대사 장애를 치료하기 위한 약제학적 병용물
CN101511364A (zh) 用于糖尿病的治疗组合
BRPI0620450A2 (pt) inibidor de dpiv para uso em combinação com metformina ou uma tiazolidinadiona e uso do referido inibidor
CN104968341B (zh) Glp1r激动剂和二甲双胍的组合及其在制备治疗2型糖尿病和其他障碍的药物中的用途
CN104582701B (zh) 减轻体重的方法
JP6412241B2 (ja) 肝機能改善法
ITMI20002019A1 (it) Metodo per il trattemento dei disturbi metabolici, in particolare diabete oppure una malattia oppure una condizione associate con il diabete
TWI519297B (zh) 使用雙醋瑞因之糖尿病輔助療法
KR20230143978A (ko) 시클로-히스프로를 유효성분으로 포함하는 당뇨병 예방 또는 치료용 약제학적 제제
AU2016206292B2 (en) A method of improving liver function
CN101272805A (zh) 包含PPARγ激动剂的药物组合物
CN106061940A (zh) 治疗糖尿病和由其引发的并发疾病的化合物
Neerjesh et al. Spotlight on pharmacology of a noble oral hypoglycaemic agent: Metformin

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20180508

Address after: Grand Cayman, Cayman Islands

Patentee after: Nayar metabolism Co., Ltd.

Address before: Vitoria Australia

Patentee before: VERVA PHARMACEUTICALS LTD

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180116

Termination date: 20210315

CF01 Termination of patent right due to non-payment of annual fee